Effectiveness and safety of filgotinib in rheumatoid arthritis: a real-life multicentre experience
Authors' conclusion
Our real-world data confirm the effectiveness and safety of filgotinib in the management of RA, especially in bDMARD-naive patients.
Study context
- Population
- Real-life multicentre cohort of rheumatoid arthritis (RA) patients treated with filgotinib
- Participants
- 126 participants
- Exposure
- Filgotinib in biologic disease-modifying anti-rheumatic drug (bDMARD)-naive vs bDMARD-IR patients, monotherapy vs with methotrexate (MTX)
- Outcome
- LDA and remission
- Follow-up
- 12 weeks
Methodological detailsreal-life, multicentre
- Real-life
- Multicentre
Main finding
As reported in the abstract
12 weeks
- Low disease activity (LDA) by simplified disease activity index (SDAI)
- 37.2 %
- Remission by SDAI
- 10.7 %
- LDA by clinical disease activity index (CDAI)
- 42.6 %
- Remission by CDAI
- 5.7 %
- LDA by DAS28-CRP
- 26.8 %
- Remission by DAS28-CRP
- 25.2 %
Observational data: associations, not effects.
Further findings
Disease activity at 24 weeks
- Significant reduction maintained for patient global assessment (PGA), examiner global assessment (EGA), visual analogue scale (VAS) pain, VAS fatigue, DAS28-CRP and C-reactive protein (CRP)
Monotherapy in bDMARD-naive vs bDMARD-IR
- Better outcomes in bDMARD-naive, with significant differences for patient reported outcomes (PROs) and DAS28-CRP
Steroid dose
- Significant decrease in all patients
Safety
Adverse events
- MACE
- 1 patient
- Increase in transaminase
- 1 patient
- Herpes zoster infections
- 0
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Effectiveness and safety of filgotinib in rheumatoid arthritis: a real-life multicentre experience. Clin Exp Rheumatol. Published 27 July 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →